# Industry Use Cases

## 1. Financial Services: Regulatory Compliance Memory

### Industry Context

Financial institutions handle thousands of regulatory updates annually from SEC, FINRA, OCC, CFPB, and international bodies. Compliance teams struggle to correlate new rules with existing obligations, identify conflicting requirements, and assess organizational impact.

### Problem

- 500+ regulatory updates per quarter across 12 jurisdictions
- Compliance officers spend 60% of time on manual cross-referencing
- Missed connections between regulations lead to $2-50M in fines
- New regulations often contradict or supersede existing ones — without explicit mention

### How the Agent Solves This

```
Continuous ingestion:
  inbox/ ← sec-rule-2026-03-amendments.pdf
  inbox/ ← finra-notice-2026-12.md
  POST /ingest ← "OCC Bulletin: Updated requirements for third-party risk management"
  POST /ingest ← "Internal audit finding: current vendor assessment doesn't cover AI vendors"

Consolidation discovers:
  Insight: "The new OCC third-party risk bulletin (March 2026) explicitly
  includes AI/ML vendors in scope. Our internal audit (Q1) already identified
  this gap. FINRA Notice 2026-12 adds reporting requirements for AI-driven
  trading decisions. Combined impact: our vendor management framework needs
  AI-specific controls by Q3, and trading desk needs new disclosure templates."

  Connections:
    OCC Bulletin ↔ Internal Audit: "Same gap identified independently"
    OCC Bulletin ↔ FINRA Notice: "Converging on AI vendor oversight"
    
Query: "What is our exposure to the new AI regulations?"
Answer: "Three converging requirements create urgency:
  1. OCC requires AI vendor risk assessments [Memory 3] — deadline Q3
  2. FINRA requires AI trading disclosures [Memory 2] — effective July
  3. Internal audit already flagged the vendor gap [Memory 4]
  Recommended: prioritize AI-specific vendor controls to satisfy all three."
```

### Business Impact

| Metric | Before | After |
|---|---|---|
| Time to assess regulatory impact | 2-3 weeks | Same day |
| Cross-regulation conflicts caught | ~40% | ~90% |
| Compliance team productivity | Baseline | 3x on cross-referencing |
| Regulatory fines from missed connections | $5M avg/year | Near zero |

---

## 2. Healthcare: Clinical Knowledge Integration

### Industry Context

Hospitals and health systems generate massive amounts of clinical data — patient outcomes, drug interaction reports, clinical trial results, protocol updates, and adverse event notifications. Connecting signals across these silos saves lives.

### Problem

- Clinical protocols updated 200+ times/year across 30 specialties
- Drug interaction databases lag behind published research by 6-18 months
- Adverse event signals scattered across incident reports, nursing notes, pharmacy alerts
- Physicians spend 4+ hours/week searching for protocol changes

### How the Agent Solves This

```
Continuous ingestion:
  POST /ingest ← "Adverse event report: Patient on Drug A + Drug B developed
                  cardiac arrhythmia. No known interaction in current database."
  inbox/ ← lancet-study-2026-drug-a-cardiac-effects.pdf
  POST /ingest ← "Pharmacy alert: Drug B recall in lot #4521 for QT prolongation"
  inbox/ ← updated-cardiology-protocol-v12.md

Consolidation discovers:
  Insight: "CRITICAL SAFETY SIGNAL: Three independent sources indicate Drug A +
  Drug B combination risk:
  1. Adverse event report (direct patient harm observed)
  2. Lancet study identifies Drug A cardiac mechanism
  3. Pharmacy recall confirms Drug B QT prolongation
  The updated cardiology protocol does NOT address this combination.
  Recommend: immediate protocol addendum and pharmacy system alert."

Query: "What cardiac risks have emerged this month?"
Answer: "Emerging signal: Drug A + Drug B combination [Memory 1, 2, 3]
  - One adverse event (arrhythmia) already occurred
  - Mechanism confirmed by Lancet study (Drug A cardiac effects)
  - Compounded by Drug B lot recall (QT prolongation)
  - Current protocol v12 has no contraindication for this combination
  Action required: update drug interaction database, notify prescribers."
```

### Business Impact

| Metric | Before | After |
|---|---|---|
| Adverse event signal detection | Weeks to months | Hours |
| Protocol update awareness | 60% of physicians within 30 days | 95% same-day |
| Drug interaction discovery (novel) | Only after multiple events | After first signal |
| Patient safety incidents (preventable) | Baseline | 40% reduction |

---

## 3. Manufacturing: Predictive Quality Intelligence

### Industry Context

Semiconductor and precision manufacturing facilities generate terabytes of sensor data, quality reports, maintenance logs, and supplier certifications. Defect root causes often span multiple systems and time periods.

### Problem

- Defect root cause analysis takes 3-14 days
- Quality issues correlate across shift reports, equipment logs, and material certificates
- Same defect patterns recur because institutional knowledge is lost during shift changes
- $500K-5M cost per day of production line downtime

### How the Agent Solves This

```
Continuous ingestion (automated from MES/SCADA):
  POST /ingest ← "Shift report: Yield dropped 3% on Line 4, operator noticed
                  slight vibration increase on spindle motor"
  POST /ingest ← "Maintenance log: Spindle bearing replaced on Line 4 (scheduled)"
  POST /ingest ← "Quality report: Lot 2026-07-240 has 2.1% defect rate
                  (surface roughness out of spec)"
  POST /ingest ← "Supplier cert: New coolant batch received, viscosity within spec
                  but 5% lower than previous batch"
  POST /ingest ← "Historical: Similar yield drop in Jan 2026 traced to coolant
                  change + bearing wear combination"

Consolidation discovers:
  Insight: "PATTERN MATCH with January 2026 incident:
  1. Bearing replacement changed spindle dynamics (vibration increase noted)
  2. New coolant batch has 5% lower viscosity (within spec but borderline)
  3. Combination of new bearing + thinner coolant = insufficient lubrication
     at high RPM, causing surface roughness defects
  4. This is the exact same failure mode as January.
  Recommended: increase coolant flow rate by 8% for Line 4 post-bearing change."

Query: "Why is Line 4 yield dropping?"
Answer: "Root cause (high confidence, matches historical pattern [Memory 5]):
  - New bearing + lower viscosity coolant = insufficient lubrication at speed
  - Same failure as January 2026 [Memory 5]
  - Fix: increase coolant flow 8% for 48 hours post-bearing replacement
  - This avoids the 3-14 day investigation cycle entirely."
```

### Business Impact

| Metric | Before | After |
|---|---|---|
| Root cause analysis time | 3-14 days | 4 hours (pattern match) |
| Recurring defect incidents | 35% of quality events are repeats | <10% |
| Production downtime cost saved | — | $2M/year (avoided investigations) |
| Knowledge retention across shifts | Poor (tribal knowledge) | 100% (persistent memory) |

---

## 4. Legal: M&A Due Diligence Intelligence

### Industry Context

Mergers & acquisitions due diligence involves reviewing thousands of documents — contracts, financial statements, IP portfolios, litigation history, regulatory filings — across the target company. Missed connections between documents cost firms millions.

### Problem

- 10,000-50,000 documents per deal
- 15-30 lawyers reviewing in parallel with limited cross-communication
- Critical risks hidden in connections between innocuous-seeming documents
- $10-100M in post-acquisition surprises from missed diligence

### How the Agent Solves This

```
Team ingestion (each lawyer feeds their review stream):
  POST /ingest ← "Contract review: Vendor X has unlimited liability clause
                  in software license. Unusual for enterprise SaaS."
  POST /ingest ← "IP review: Patent #12345 licensed from Vendor X,
                  exclusive until 2028. Core to product line A."
  POST /ingest ← "Litigation: Vendor X sued by CompetitorY for patent
                  infringement (Patent #12345). Filed March 2026."
  POST /ingest ← "Financial: Product line A generates 40% of target revenue"

Consolidation discovers:
  Insight: "CRITICAL DEAL RISK identified across 4 review streams:
  1. Product line A (40% revenue) depends on Patent #12345 [Financial + IP]
  2. Patent #12345 is licensed from Vendor X [IP review]
  3. Vendor X is being sued for infringement ON that patent [Litigation]
  4. If Vendor X loses, license may be invalidated
  5. Unusual liability clause suggests Vendor X may already be hedging [Contract]
  
  Impact: 40% of target revenue at risk from single patent dispute.
  This was invisible to any individual reviewer — only the cross-stream
  connection reveals the compound risk."

Query: "What are the top 3 deal risks?"
Answer: "1. Patent dependency chain: 40% revenue at risk [Memory 1-4, Insight 1]
  2. [other risks from memory]
  3. [other risks from memory]
  Priority: Patent #12345 risk requires immediate deep-dive before deal proceeds."
```

### Business Impact

| Metric | Before | After |
|---|---|---|
| Cross-document risk discovery | 30% (limited by reviewer communication) | 85%+ |
| Time to identify compound risks | Often post-close (too late) | During diligence |
| Deal value adjustment accuracy | Baseline | 25% more accurate pricing |
| Post-acquisition surprises | 3-5 material issues per deal | 0-1 |

---

## 5. Cybersecurity: Threat Intelligence Correlation

### Industry Context

Security Operations Centers (SOC) process thousands of alerts, threat feeds, vulnerability reports, and incident data daily. The signal-to-noise ratio is brutal. Advanced threats are identified by correlating weak signals across time and sources.

### Problem

- 10,000+ alerts per day, 95% are noise
- APT campaigns unfold over weeks/months with individually innocuous indicators
- Threat intel arrives from 15+ feeds in different formats
- Mean time to detect (MTTD) for advanced threats: 197 days (IBM 2024)

### How the Agent Solves This

```
Continuous ingestion (from SIEM, feeds, reports):
  POST /ingest ← "SIEM: Unusual DNS queries to newly registered domain
                  from finance-server-03. Low confidence alert."
  POST /ingest ← "Threat feed: APT-41 campaign using DNS tunneling to
                  NRDs registered in past 7 days. Target: financial services."
  POST /ingest ← "Vuln scan: finance-server-03 running unpatched Log4j
                  (CVE-2021-44228). Remediation overdue 90 days."
  POST /ingest ← "HR system: New contractor started in finance dept last week.
                  VPN access provisioned to finance subnet."

Consolidation discovers:
  Insight: "HIGH CONFIDENCE THREAT CORRELATION:
  1. finance-server-03 querying newly registered domains [SIEM - weak signal alone]
  2. APT-41 actively using DNS tunneling to NRDs against financial services [Intel]
  3. Same server has unpatched Log4j — known APT-41 initial access vector [Vuln]
  4. New contractor with finance access = potential insider or compromised credential
  
  Individual signals: low/medium confidence
  Combined signal: HIGH confidence APT-41 indicator
  
  Recommended: isolate finance-server-03, audit contractor access,
  deploy DNS sinkhole for identified NRDs."

Query: "Is finance-server-03 compromised?"
Answer: "Assessment: LIKELY COMPROMISED (high confidence)
  Evidence chain:
  - DNS tunneling behavior matches APT-41 TTP [Memory 1, 2]
  - Unpatched Log4j provides initial access path [Memory 3]
  - Timeline correlates with new contractor access [Memory 4]
  Immediate actions: network isolation, forensic image, credential rotation."
```

### Business Impact

| Metric | Before | After |
|---|---|---|
| Mean time to detect (MTTD) | 197 days | Hours (pattern correlation) |
| Alert triage efficiency | 5% true positive rate | 40%+ (pre-correlated) |
| SOC analyst investigation time | 4 hours per true positive | 30 minutes (context provided) |
| Breach cost avoided | — | $4.5M average breach cost (IBM) |

---

## 6. Pharmaceutical: Drug Development Intelligence

### Industry Context

Drug development involves 10-15 years of research, clinical trials, regulatory interactions, and competitor intelligence. Knowledge fragments across hundreds of scientists, thousands of papers, and decades of internal data.

### Problem

- $2.6B average cost to bring a drug to market
- 90% failure rate in clinical trials
- Competitor intelligence arrives months after strategic decisions
- Internal R&D silos mean the biology team doesn't see the regulatory team's signals

### How the Agent Solves This

```
Cross-team ingestion:
  POST /ingest ← "Clinical: Phase 2a shows 23% response rate for compound X
                  in indication A. Below threshold for advancement."
  POST /ingest ← "Biology: Biomarker Y correlates with response in preclinical
                  models. 35% of patients in Phase 2a had high Biomarker Y."
  POST /ingest ← "Competitor: PharmaCo presented Phase 1 data for similar MOA.
                  Their trial uses Biomarker Y enrichment strategy."
  POST /ingest ← "Regulatory: FDA guidance update allows biomarker-enriched
                  trials with smaller N for accelerated approval."

Consolidation discovers:
  Insight: "COMPOUND X RESCUE STRATEGY:
  1. Overall response (23%) below threshold — but this is diluted by non-responders
  2. Biomarker Y predicts response — enriching for Biomarker Y+ patients would
     yield ~60% response rate (23% / 0.35 subset)
  3. Competitor already using this enrichment strategy (validates approach)
  4. New FDA guidance enables smaller enriched trial with accelerated pathway
  
  Recommendation: Don't terminate compound X. Redesign Phase 2b as
  Biomarker Y-enriched trial. Smaller N, faster timeline, higher
  probability of success. Competitive pressure requires speed."

Query: "Should we kill compound X?"
Answer: "No. Recommend biomarker-enriched redesign [Memory 1-4]:
  - Enriched population response: ~60% (well above threshold)
  - FDA pathway available for smaller trial [Memory 4]
  - Competitor validates the approach [Memory 3]
  - Risk of termination: lose 3 years of work + $400M sunk cost
  - Risk of enriched trial: 12 months + $50M to definitive answer"
```

### Business Impact

| Metric | Before | After |
|---|---|---|
| Drug program terminations (premature) | 15% could have been rescued | <5% |
| Time to competitive intelligence integration | 3-6 months | Same week |
| Cross-functional insight generation | Quarterly reviews only | Continuous |
| Cost savings per rescued program | — | $200-500M |

---

## Cross-Industry Pattern

Every industry use case shares the same structure:

```
FRAGMENTED SIGNALS          →  CONSOLIDATION  →  COMPOUND INSIGHT
(individually low-value)                         (high-value, actionable)

Finance:  regulation + audit + notice     →  converging AI oversight requirement
Health:   adverse event + study + recall  →  novel drug interaction signal
Mfg:      vibration + coolant + history   →  known failure mode recurring
Legal:    contract + patent + lawsuit     →  compound deal risk
Cyber:    DNS + threat feed + vuln + HR   →  APT campaign in progress
Pharma:   trial data + biomarker + FDA    →  rescue strategy for failing drug
```

The agent's value is **not** in storing information (any database does that). The value is in **automatically discovering connections that span sources, teams, and time** — connections that humans miss because no single person holds all the pieces.

---

## Deployment Patterns by Industry

| Industry | Deployment | Database | Model | Compliance |
|---|---|---|---|---|
| Financial Services | Private VPC, no internet | Aurora PostgreSQL | Claude (Bedrock) | SOC 2, encrypt at rest |
| Healthcare | HIPAA-compliant AWS | RDS PostgreSQL | Claude (Bedrock) | BAA, audit logging |
| Manufacturing | On-premises Docker | SQLite (air-gapped) | Nova Lite | OT network isolated |
| Legal | Client-specific instances | Separate DB per matter | Claude Sonnet | Privilege, data walls |
| Cybersecurity | SOC-integrated, real-time | PostgreSQL + TimescaleDB | Claude Haiku | FedRAMP (GovCloud) |
| Pharmaceutical | AWS GxP-validated | Aurora + S3 versioning | Claude | 21 CFR Part 11, audit trail |

---

## ROI Framework

```
Value = (Insights Discovered × Value Per Insight) − (LLM Cost + Infrastructure)

Where:
  Insights/month:        10-50 (depends on ingestion volume)
  Value/insight:         $10K-$10M (depends on industry)
  LLM cost:             $3-30/month
  Infrastructure:        $0 (SQLite) to $50/month (managed Postgres)

Conservative ROI:
  10 insights × $10K average value = $100K/month
  Cost: $50/month
  ROI: 2000x
```

The asymmetry is extreme: the cost of finding one missed regulatory connection, one patient safety signal, or one deal risk dwarfs years of agent operation costs.
